Summary & Overview
HCPCS J0688: Cefazolin Sodium (Hikma) Injection, 500 mg
HCPCS Level II code J0688 identifies a 500 mg injection of cefazolin sodium (Hikma) that is designated as not therapeutically equivalent to J0690. This injectable cephalosporin is commonly used for perioperative prophylaxis and treatment of susceptible bacterial infections in clinical settings that deliver parenteral antibiotics. Nationally, accurate coding for branded or non-equivalent biologic and pharmaceutical products matters for benefit administration, payer coverage determinations, and facility billing workflows.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find a concise review of clinical context for parenteral cefazolin, payer coverage considerations, and common billing practices tied to HCPCS reporting. The publication outlines typical sites of service, coding nuances distinguishing non-equivalent product codes, and practical information on related service-line classification. Where input data is not provided, the text notes that specific items (for example, associated taxonomies or ICD-10 pairings) are not available in the input.
This summary equips billing managers, revenue cycle staff, and policy analysts with the essential facts about HCPCS Level II code J0688, enabling clearer communication with clinical teams and payers about administration and coding of this specific cefazolin product.
Billing Code Overview
HCPCS Level II code J0688 describes an injection of cefazolin sodium (Hikma), 500 mg, specified as not therapeutically equivalent to J0690. The service type is an antibiotic injection administered parenterally. The typical site of service is outpatient or inpatient clinical settings where intravenous or intramuscular antibiotic administration occurs, including hospital inpatient units, hospital outpatient departments, emergency departments, and outpatient infusion centers.
Clinical & Coding Specifications
Clinical Context
A 56-year-old male presents to the outpatient infusion clinic with a diagnosed soft-tissue infection of the lower extremity following a diabetic foot ulcer. The treating provider orders intravenous cefazolin for empirical Gram-positive coverage while wound cultures are pending. Pharmacy dispenses J0688 (Injection, cefazolin sodium (hikma), not therapeutically equivalent to J0690, 500 mg). The patient is prepped in the clinic’s procedure area, allergy review and renal function checks are confirmed, and the dose is administered via peripheral IV by an infusion nurse. Documentation includes indication, dose, lot number, route, start and stop times, site of administration, and any immediate adverse reactions. Billing captures the HCPCS Level II code J0688 for the drug and an appropriate administration CPT for IV push or infusion as per facility policy; modifiers are appended if clinically applicable (for example, modifier JW if part of the drug is discarded). Typical sites of service include outpatient infusion centers, emergency departments, observation units, ambulatory surgery centers when used perioperatively, and inpatient floors for IV antibiotic therapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW |